Oral squamous cell carcinomas: state of the field and emerging directions

Vigneswaran, N. & Williams, M. D. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac. Surg. Clin. 26, 123–141 (2014).

Ng, J. H., Iyer, N. G., Tan, M.-H. & Edgren, G. Changing epidemiology of oral squamous cell carcinoma of the tongue: a global study. Head Neck 39, 297–304 (2017).

Mody, M. D., Rocco, J. W., Yom, S. S., Haddad, R. I. & Saba, N. F. Head and neck cancer. Lancet 398, 2289–2299 (2021).

Romano, A. et al. Noninvasive imaging methods to improve the diagnosis of oral carcinoma and its precursors: state of the art and proposal of a three-step diagnostic process. Cancers 13, 2864 (2021).

Safi, A.-F. et al. Clinicopathological parameters affecting nodal yields in patients with oral squamous cell carcinoma receiving selective neck dissection. J. Cranio-Maxillofac. Surg. 45, 2092–2096 (2017).

Linsen, S. S., Gellrich, N.-C. & Krüskemper, G. Age-and localization-dependent functional and psychosocial impairments and health related quality of life six months after OSCC therapy. Oral Oncol. 81, 61–68 (2018).

Meier, J. K. et al. Health-related quality of life: a retrospective study on local vs. microvascular reconstruction in patients with oral cancer. BMC Oral Health 19, 1–8 (2019).

Maymone, M. B. C. et al. Premalignant and malignant oral mucosal lesions: Clinical and pathological findings. J. Am. Acad. Dermatol. 81, 59–71 (2019).

Odell, E., Kujan, O., Warnakulasuriya, S. & Sloan, P. Oral epithelial dysplasia: recognition, grading and clinical significance. Oral Dis. 27, 1947–1976 (2021).

Brandizzi, D., Gandolfo, M., Velazco, M. L., Cabrini, R. L. & Lanfranchi, H. Clinical features and evolution of oral cancer: a study of 274 cases in Buenos Aires, Argentina. Med. Oral Patol. Oral Cir. Bucal. 13, E544-8 (2008).

Bagan, J., Sarrion, G. & Jimenez, Y. Oral cancer: clinical features. Oral Oncol. 46, 414–417 (2010).

Scully, C. & Bagan, J. V. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis. 15, 388–399 (2009).

Harada, H. et al. Characteristics of oral squamous cell carcinoma focusing on cases unaffected by smoking and drinking: a multicenter retrospective study. Head Neck 45, 1812–1822 (2023).

Omura, K. Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma. Int. J. Clin. Oncol. 19, 423–430 (2014).

Jerjes, W. et al. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head Neck Oncol. 2, 1–21 (2010).

Warnakulasuriya, S. Oral potentially malignant disorders: A comprehensive review on clinical aspects and management. Oral Oncol. 102, 104550 (2020).

Yap, T. et al. Non-invasive screening of a microRNA-based dysregulation signature in oral cancer and oral potentially malignant disorders. Oral Oncol. 96, 113–120 (2019).

Chuang, S.-L. et al. Malignant transformation to oral cancer by subtype of oral potentially malignant disorder: a prospective cohort study of Taiwanese nationwide oral cancer screening program. Oral Oncol. 87, 58–63 (2018).

Warnakulasuriya, S. Clinical features and presentation of oral potentially malignant disorders. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 125, 582–590 (2018).

Dionne, K. R., Warnakulasuriya, S., Binti Zain, R. & Cheong, S. C. Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory. Int. J. Cancer 136, 503–515 (2015).

Tarakji, B. Dentists’ perception of oral potentially malignant disorders. Int. Dent. J. 72, 414–419 (2022).

Kerr, A. R. & Lodi, G. Management of oral potentially malignant disorders. Oral Dis. 27, 2008–2025 (2021).

Mello, F. W. et al. Prevalence of oral potentially malignant disorders: a systematic review and meta‐analysis. J. Oral Pathol. Med. 47, 633–640 (2018).

Warnakulasuriya, S., Johnson, N. W. & van der Waal, I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J. Oral Pathol. Med. 36, 575–580 (2007).

Villa, A. & Sonis, S. Oral leukoplakia remains a challenging condition. Oral Dis. 24, 179–183 (2018).

Holmstrup, P. & Dabelsteen, E. Oral leukoplakia—to treat or not to treat. Oral Dis. 22, 494–497 (2016).

Carrard, V. C. & van der Waal, I. A clinical diagnosis of oral leukoplakia; A guide for dentists. Med. Oral Patol. Oral Cir. Bucal 23, e59 (2018).

Warnakulasuriya, S. et al. Oral potentially malignant disorders: a consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 27, 1862–1880 (2021).

Speight, P. M., Khurram, S. A. & Kujan, O. Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 125, 612–627 (2018).

Pentenero, M., Meleti, M., Vescovi, P. & Gandolfo, S. Oral proliferative verrucous leucoplakia: are there particular features for such an ambiguous entity? A systematic review. Br. J. Dermatol. 170, 1039–1047 (2014).

Cabay, R. J., Morton, T. H. Jr & Epstein, J. B. Proliferative verrucous leukoplakia and its progression to oral carcinoma: a review of the literature. J. Oral Pathol. Med. 36, 255–261 (2007).

Yang, S.-W., Lee, Y.-S., Chang, L.-C., Hsieh, T.-Y. & Chen, T.-A. Outcome of excision of oral erythroplakia. Br. J. Oral Maxillofac. Surg. 53, 142–147 (2015).

Boy, S. C. Leukoplakia and erythroplakia of the oral mucosa—a brief overview. SADJ 67, 558–560 (2012).

Holmstrup, P. Oral erythroplakia—what is it? Oral Dis. 24, 138–143 (2018).

Yang, S.-W. et al. Clinical characteristics of narrow-band imaging of oral erythroplakia and its correlation with pathology. BMC Cancer 15, 1–8 (2015).

Boy, S. C. Leukoplakia and erythroplakia of the oral mucosa-a brief overview: clinical review. SADJ 67, 558–560 (2012).

Tilakaratne, W. M., Ekanayaka, R. P. & Warnakulasuriya, S. Oral submucous fibrosis: a historical perspective and a review on etiology and pathogenesis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 122, 178–191 (2016).

Qin, X., Ning, Y., Zhou, L. & Zhu, Y. Oral submucous fibrosis: etiological mechanism, malignant transformation, therapeutic approaches and targets. Int. J. Mol. Sci. 24, 4992 (2023).

Shen, Y.-W., Shih, Y.-H., Fuh, L.-J. & Shieh, T.-M. Oral submucous fibrosis: a review on biomarkers, pathogenic mechanisms, and treatments. Int. J. Mol. Sci. 21, 7231 (2020).

Peng, Q., Li, H., Chen, J., Wang, Y. & Tang, Z. Oral submucous fibrosis in Asian countries. J. Oral Pathol. Med. 49, 294–304 (2020).

Al‐Hassiny, A. et al. Upregulation of angiogenesis in oral lichen planus. J. Oral Pathol. Med. 47, 173–178 (2018).

De Rossi, S. S. & Ciarrocca, K. Oral lichen planus and lichenoid mucositis. Dent. Clin. 58, 299–313 (2014).

Aghbari, S. M. H. et al. Malignant transformation of oral lichen planus and oral lichenoid lesions: a meta-analysis of 20095 patient data. Oral Oncol. 68, 92–102 (2017).

González‐Moles, M. Á. et al. Worldwide prevalence of oral lichen planus: a systematic review and meta‐analysis. Oral Dis. 27, 813–828 (2021).

Nogueira, P. A., Carneiro, S. & Ramos‐e‐Silva, M. Oral lichen planus: an update on its pathogenesis. Int. J. Dermatol. 54, 1005–1010 (2015).

Ahmadi, N. et al. Association of PD-L1 expression in oral squamous cell carcinoma with smoking, sex, and p53 expression. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 128, 631–638 (2019).

Wang, X., Xu, J., Wang, L., Liu, C. & Wang, H. The role of cigarette smoking and alcohol consumption in the differentiation of oral squamous cell carcinoma for the males in China. J. Cancer Res. Therapeut. 11, 141–145 (2015).

Dong, J. & Thrift, A. P. Alcohol, smoking and risk of oesophago-gastric cancer. Best Pract. Res. Clin. Gastroenterol. 31, 509–517 (2017).

Matejcic, M., Gunter, M. J. & Ferrari, P. Alcohol metabolism and oesophageal cancer: a systematic review of the evidence. Carcinogenesis 38, 859–872 (2017).

Ghantous, Y., Schussel, J. L. & Brait, M. Tobacco and alcohol induced epigenetic changes in oral carcinoma. Curr. Opin. Oncol. 30, 152 (2018).

Zhang, P. et al. Molecular mechanisms of malignant transformation of oral submucous fibrosis by different betel quid constituents—does fibroblast senescence play a role? Int. J. Mol. Sci. 23, 1637 (2022).

Ko, A. M.-S., Lee, C.-H. & Ko, Y.-C. Betel quid–associated cancer: Prevention strategies and targeted treatment. Cancer Lett. 477, 60–69 (2020).

Singh, V. et al. p16 and p53 in HPV‐positive versus HPV‐negative oral squamous cell carcinoma: do pathways differ? J. Oral Pathol. Med. 46, 744–751 (2017).

Purwanto, D. J. et al. The prevalence of oral high‐risk HPV infection in Indonesian oral squamous cell carcinoma patients. Oral Dis. 26, 72–80 (2020).

Wolfer, S., Foos, T., Kunzler, A., Ernst, C. & Schultze-Mosgau, S. Association of the preoperative body mass index with postoperative complications after treatment of oral squamous cell carcinoma. J. Oral Maxillofac. Surg. 76, 1800–1815 (2018).

Eckert, A. W. et al. Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. J. Transl. Med. 14, 1–13 (2016).

Ram, H. et al. Oral cancer: risk factors and molecular pathogenesis. J. Maxillofac. Oral Surg. 10, 132–137 (2011).

Cheng, T. Chemical evaluation of electronic cigarettes. Tob. Control 23, ii11–ii17 (2014).

Boffetta, P. & Hashibe, M. Alcohol and cancer. Lancet Oncol. 7, 149–156 (2006).

Jeng, J.-H., Chang, M. C. & Hahn, L. J. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol. 37, 477–492 (2001).

Rehman, K., Fatima, F., Waheed, I. & Akash, M. S. H. Prevalence of exposure of heavy metals and their impact on health consequences. J. Cell. Biochem. 119, 157–184 (2018).

Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C. & Wacholder, S. Human papillomavirus and cervical cancer. Lancet 370, 890–907 (2007).

Kouketsu, A. et al. Detection of human papillomavirus infection in oral squamous cell carcinoma: a cohort study of Japanese patients. J. Oral Pathol. Med. 45, 565–572 (2016).

Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E. & Feldman, B. J. The role of vitamin D in reducing cancer risk and progression. Nat. Rev. Cancer 14, 342–357 (2014).

Stechschulte, S. A., Kirsner, R. S. & Federman, D. G. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am. J. Med. 122, 793–802 (2009).

Ribeiro, F. A. P., Noguti, J., Oshima, C. T. F. & Ribeiro, D. A. Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach. Anticancer Res. 34, 1547–1552 (2014).

Liu, F. & Millar, S. Wnt/β-catenin signaling in oral tissue development and disease. J. Dent. Res. 89, 318–330 (2010).

Huang, J.-S. et al. Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction. BMC Cancer 16, 1–13 (2016).

Ali, J. et al. Genetic etiology of oral cancer. Oral Oncol. 70, 23–28 (2017).

Simpson, D. R., Mell, L. K. & Cohen, E. E. W. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 51, 291–298 (2015).

Speight, P. M. et al. Screening for oral cancer—a perspective from the Global Oral Cancer Forum. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 123, 680–687 (2017).

Zhang, J. et al. Attenuated TRAF3 fosters activation of alternative NF-κB and reduced expression of antiviral interferon, TP53, and RB to promote HPV-positive head and neck cancers decreased TRAF3 promotes HPV+ HNSCC. Cancer Res. 78, 4613–4626 (2018).

Vijayalakshmi, N., Selvaluxmi, G., Majhi, U. & Rajkumar, T. Alterations found in p16/RB/Cyclin D1 pathway in the dysplastic and malignant cervical epithelium. Oncol. Res. 16, 527–533 (2007).

Shridhar, K. et al. DNA methylation markers for oral pre-cancer progression: A critical review. Oral Oncol. 53, 1–9 (2016).

Wang, Y. et al. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer. Cancer Lett. 374, 12–21 (2016).

Portney, B. A. et al. ZSCAN4 facilitates chromatin remodeling and promotes the cancer stem cell phenotype. Oncogene 39, 4970–4982 (2020).

Irimie, A. I. et al. A looking-glass of non-coding RNAs in oral cancer. Int. J. Mol. Sci. 18, 2620 (2017).

Elmusrati, A., Wang, J. & Wang, C.-Y. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int. J. Oral Sci. 13, 1–11 (2021).

Haas, L. et al. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nat. Cancer 2, 693–708 (2021).

Teles, F. R., Alawi, F., Castilho, R. M. & Wang, Y. Association or causation? Exploring the oral microbiome and cancer links. J. Dent. Res. 99, 1411–1424 (2020).

Salahshourifar, I., Vincent-Chong, V. K., Kallarakkal, T. G. & Zain, R. B. Genomic DNA copy number alterations from precursor oral lesions to oral squamous cell carcinoma. Oral Oncol. 50, 404–412 (2014).

Ishida, K. et al. Current mouse models of oral squamous cell carcinoma: genetic and chemically induced models. Oral Oncol. 73, 16–20 (2017).

Fadlullah, M. Z. H. et al. Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. Oncotarget 7, 27802 (2016).

Gillison, M. L. et al. Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Res. 29, 1–17 (2019).

Li, Q., Tie, Y., Alu, A., Ma, X. & Shi, H. Targeted therapy for head and neck cancer: Signaling pathways and clinical studies. Signal. Transduct. Target. Ther. 8, 31 (2023).

Chung, C. H. et al. Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma. Head Neck 39, E15–E19 (2017).

Concha-Benavente, F. et al. Identification of the cell-intrinsic and-extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer. Cancer Res. 76, 1031–1043 (2016).

Alsahafi, E. et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis. 10, 540 (2019).

Laimer, K. et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol. 43, 193–198 (2007).

Szturz, P. & Vermorken, J. B. Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. Oral Oncol. 101, 104492 (2020).

Brand, T. M. et al. Nuclear EGFR as a molecular target in cancer. Radiother. Oncol. 108, 370–377 (2013).

Vouri, M. et al. Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells. Oncogenesis 5, e266–e266 (2016).

Su, W. et al. Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway. BMC Cancer 19, 1–13 (2019).

Liang, J., Liu, J., Deng, Z., Liu, Z. & Liang, L. DLX6 promotes cell proliferation and survival in oral squamous cell carcinoma. Oral Dis. 28, 87–96 (2022).

Jin, H., Zhang, L., Wang, S. & Qian, L. BST2 promotes growth and induces gefitinib resistance in oral squamous cell carcinoma via regulating the EGFR pathway. Arch. Med. Sci. 17, 1772 (2021).

Cochicho, D. et al. PIK3CA gene mutations in HNSCC: systematic review and correlations with HPV status and patient survival. Cancers 14, 1286 (2022).

Kang, H., Kiess, A. & Chung, C. H. Emerging biomarkers in head and neck cancer in the era of genomics. Nat. Rev. Clin. Oncol. 12, 11–26 (2015).

Peng, C.-H. et al. Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma. Oncotarget 6, 19891 (2015).

Marquard, F. E. & Jücker, M. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem. Pharmacol. 172, 113729 (2020).

Ghafouri-Fard, S. et al. Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers. Cancer Cell Int. 22, 1–27 (2022).

Cully, M., You, H., Levine, A. J. & Mak, T. W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184–192 (2006).

Ito, K. et al. Inhibition of Nox1 induces apoptosis by attenuating the AKT signaling pathway in oral squamous cell carcinoma cell lines. Oncol. Rep. 36, 2991–2998 (2016).

Kupferman, M. E. & Myers, J. N. Molecular biology of oral cavity squamous cell carcinoma. Otolaryngol. Clin. North Am. 39, 229–247 (2006).

Zhou, Q. et al. ATP promotes oral squamous cell carcinoma cell invasion and migration by activating the PI3K/AKT pathway via the P2Y2-Src-EGFR axis. ACS Omega 7, 39760–39771 (2022).

Wang, J. et al. The circEPSTI1/mir-942-5p/LTBP2 axis regulates the progression of OSCC in the background of OSF via EMT and the PI3K/Akt/mTOR pathway. Cell Death Dis. 11, 682 (2020).

Zhang, X. et al. ITGB2-mediated metabolic switch in CAFs promotes OSCC proliferation by oxidation of NADH in mitochondrial oxidative phosphorylation system. Theranostics 10, 12044 (2020).

Wang, H. et al. Elevated expression of zinc finger protein 703 promotes cell proliferation and metastasis through PI3K/AKT/GSK-3β signalling in oral squamous cell carcinoma. Cell. Physiol. Biochem. 44, 920–934 (2017).

Zhang, H., Sun, J.-D., Yan, L. & Zhao, X.-P. PDGF-D/PDGFRβ promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway. Biochem. Biophys. Res. Commun. 478, 845–851 (2016).

Jiang, X. et al. Elevated autocrine chemokine ligand 18 expression promotes oral cancer cell growth and invasion via Akt activation. Oncotarget 7, 16262 (2016).

Li, P., Xiao, L. Y. & Tan, H. Muc-1 promotes migration and invasion of oral squamous cell carcinoma cells via PI3K-Akt signaling. Int. J. Clin. Exp. Pathol. 8, 10365 (2015).

Yang, H. et al. FoxM1 promotes epithelial–mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loop. Anti-Cancer Drugs 29, 216 (2018).

Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK/STAT signaling pathway: from bench to clinic. Signal. Transduct. Target. Ther. 6, 402 (2021).

Geiger, J. L., Grandis, J. R. & Bauman, J. E. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 56, 84–92 (2016).

Avalle, L. et al. STAT3 localizes to the ER, acting as a gatekeeper for ER-mitochondrion Ca2+ fluxes and apoptotic responses. Cell Death Differ. 26, 932–942 (2019).

Bu, L. L. et al. STAT3 induces immunosuppression by upregulating PD-1/PD-L1 in HNSCC. J. Dent. Res. 96, 1027–1034 (2017).

Yu, H., Lee, H., Herrmann, A., Buettner, R. & Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14, 736–746 (2014).

Tan, J., Xiang, L. & Xu, G. LncRNA MEG3 suppresses migration and promotes apoptosis by sponging miR‐548d‐3p to modulate JAK–STAT pathway in oral squamous cell carcinoma. IUBMB Life 71, 882–890 (2019).

Zhang, X. et al. Long non-coding RNA P4713 contributes to the malignant phenotypes of oral squamous cell carcinoma by activating the JAK/STAT3 pathway. Int. J. Clin. Exp. Pathol. 10, 10947 (2017).

Cho, Y. A. et al. Alteration status and prognostic value of MET in head and neck squamous cell carcinoma. J. Cancer 7, 2197 (2016).

Seiwert, T. Y. et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021–3031 (2009).

Hartmann, S., Bhola, N. E. & Grandis, J. R. HGF/Met signaling in head and neck cancer: impact on the tumor microenvironment. Clin. Cancer Res. 22, 4005–4013 (2016).

Moosavi, F., Giovannetti, E., Saso, L. & Firuzi, O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit. Rev. Clin. Lab. Sci. 56, 533–566 (2019).

Knowles, L. M. et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin. Cancer Res. 15, 3740–3750 (2009).

Szturz, P. et al. Understanding c-MET signalling in squamous cell carcinoma of the head & neck. Crit. Rev. Oncol./Hematol. 111, 39–51 (2017).

Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).

Huang, W.-C. et al. A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing β5-integrin/c-met signaling pathway. J. Exp. Clin. Cancer Res. 38, 1–17 (2019).

Alamoud, K. A. & Kukuruzinska, M. A. Emerging insights into Wnt/β-catenin signaling in head and neck cancer. J. Dent. Res. 97, 665–673 (2018).

Moon, J. H., Lee, S. H. & Lim, Y. C. Wnt/β-catenin/Slug pathway contributes to tumor invasion and lymph node metastasis in head and neck squamous cell carcinoma. Clin. Exp. Metastasis 38, 163–174 (2021).

Xie, J. et al. Cancer‐associated fibroblasts secrete hypoxia‐induced serglycin to promote head and neck squamous cell carcinoma tumor cell growth in vitro and in vivo by activating the Wnt/β-catenin pathway. Cell. Oncol. 44, 661–671 (2021).

Hiremath, I. S. et al. The multidimensional role of the Wnt/β‐catenin signaling pathway in human malignancies. J. Cell. Physiol. 237, 199–238 (2022).

Chamoli, A. et al. Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. Oral Oncol. 121, 105451 (2021).

Wang, X. et al. Histone methyltransferase KMT2D cooperates with MEF2A to promote the stem-like properties of oral squamous cell carcinoma. Cell Biosci. 12, 1–13 (2022).

Qiao, C., Qiao, T., Yang, S., Liu, L. & Zheng, M. SNHG17/miR-384/ELF1 axis promotes cell growth by transcriptional regulation of CTNNB1 to activate Wnt/β-catenin pathway in oral squamous cell carcinoma. Cancer Gene Ther. 29, 122–132 (2022).

Huang, G. et al. Glycolysis-Related Gene Analyses Indicate That DEPDC1 Promotes the Malignant Progression of Oral Squamous Cell Carcinoma via the WNT/β-Catenin Signaling Pathway. Int. J. Mol. Sci. 24, 1992 (2023).

Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576 (2015).

Tsuchiya, R. et al. Expression of adenomatous polyposis coli (APC) in tumorigenesis of human oral squamous cell carcinoma. Oral Oncol. 40, 932–940 (2004).

Shiah, S.-G. et al. Downregulated miR329 and miR410 promote the proliferation and invasion of oral squamous cell carcinoma by targeting Wnt-7bmiR329 and miR410 regulate Wnt–β-Catenin signaling pathway. Cancer Res. 74, 7560–7572 (2014).

Xie, H. et al. WNT7A promotes EGF-induced migration of oral squamous cell carcinoma cells by activating β-catenin/MMP9-mediated signaling. Front. Pharmacol. 11, 98 (2020).

Chiba, T. et al. MALT1 inhibition of oral carcinoma cell invasion and ERK/MAPK activation. J. Dent. Res. 95, 446–452 (2016).

Rezatabar, S. et al. RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression. J. Cell. Physiol. 234, 14951–14965 (2019).

Peng, Q. et al. Mitogen-activated protein kinase signaling pathway in oral cancer. Oncol. Lett. 15, 1379–1388 (2018).

Tao, Y. et al. SH3-domain binding protein 1 in the tumor microenvironment promotes hepatocellular carcinoma metastasis through WAVE2 pathway. Oncotarget 7, 18356 (2016).

Shimizu, T. et al. Annexin A10 in human oral cancer: biomarker for tumoral growth via G1/S transition by targeting MAPK signaling pathways. PLoS ONE 7, e45510 (2012).

Turner, N. & Grose, R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 10, 116–129 (2010).

Sigismund, S., Avanzato, D. & Lanzetti, L. Emerging functions of the EGFR in cancer. Mol. Oncol. 12, 3–20 (2018).

Hu, W. et al. Extracellular vesicles-released parathyroid hormone-related protein from Lewis lung carcinoma induces lipolysis and adipose tissue browning in cancer cachexia. Cell Death Dis. 12, 1–14 (2021).

Carbone, C. et al. Angiopoietin-like proteins in angiogenesis, inflammation and cancer. Int. J. Mol. Sci. 19, 431 (2018).

Wang, S. et al. Quaking 5 suppresses TGF‐β‐induced EMT and cell invasion in lung adenocarcinoma. EMBO Rep. 22, e52079 (2021).

Artemenko, M., Zhong, S. S. W., To, S. K. Y. & Wong, A. S. T. p70 S6 kinase as a therapeutic target in cancers: More than just an mTOR effector. Cancer Lett. 535, 215593 (2022).

Kim, M. P. & Lozano, G. Mutant p53 partners in crime. Cell Death Differ. 25, 161–168 (2018).

Lindemann, A., Takahashi, H., Patel, A. A., Osman, A. A. & Myers, J. N. Targeting the DNA damage response in OSCC with TP 53 mutations. J. Dent. Res. 97, 635–644 (2018).

Ara, N., Atique, M., Ahmed, S. & Ali Bukhari, S. G. Frequency of p53 gene mutation and protein expression in oral squamous cell carcinoma. J. Coll. Phys. Surg. Pak. 24, 749–753 (2014).

Castellsagué, X. et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J. Natl Cancer Inst. 108, djv403 (2016).

Yang, L. et al. The expression and correlation of iNOS and p53 in oral squamous cell carcinoma. BioMed. Res. Int. 2015, 637853 (2015).

Yang, X.-H. et al. p53-positive expression in dysplastic surgical margins is a predictor of tumor recurrence in patients with early oral squamous cell carcinoma. Cancer Manag. Res. 11, 1465 (2019).

Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154–1157 (2011).

Hang, W. et al. Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1. Oncogene 37, 3384–3398 (2018).

Jun, H. J. et al. A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nat. Commun. 9, 1–13 (2018).

Cierpikowski, P., Lis-Nawara, A., Gajdzis, P. & Bar, J. PDGFRα/HER2 and PDGFRα/p53 co-expression in oral squamous cell carcinoma. Anticancer Res. 38, 795–802 (2018).

Gipson, B. J., Robbins, H. A., Fakhry, C. & D’Souza, G. Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer. Oral Oncol. 77, 52–56 (2018).

Soni, S. et al. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 68, 314–325 (2005).

Rayess, H., Wang, M. B. & Srivatsan, E. S. Cellular senescence and tumor suppressor gene p16. Int. J. Cancer 130, 1715–1725 (2012).

Nemes, J. A., Deli, L., Nemes, Z. & Márton, I. J. Expression of p16INK4A, p53, and Rb proteins are independent from the presence of human papillomavirus genes in oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol. 102, 344–352 (2006).

Salehinejad, J. et al. Immunohistochemical expression of p16 protein in oral squamous cell carcinoma and lichen planus. Ann. Diagn. Pathol. 18, 210–213 (2014).

Suzuki, H., Sugimura, H. & Hashimoto, K. p16INK4A in oral squamous cell carcinomas—a correlation with biological behaviors: immunohistochemical and FISH analysis. J. Oral Maxillofac. Surg. 64, 1617–1623 (2006).

Hanken, H. et al. CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clin. Oral Investig. 18, 269–276 (2014).

Monteiro, L. S. et al. Prognostic significance of cyclins A2, B1, D1, and E1 and CCND1 numerical aberrations in oral squamous cell carcinomas. Anal. Cell. Pathol. 2018, 7253510 (2018).

Ramos-García, P. et al. Clinicopathological significance of tumor cyclin D1 expression in oral cancer. Arch. Oral Biol. 99, 177–182 (2019).

Ramos-García, P. et al. Asymmetrical proliferative pattern loss linked to cyclin D1 overexpression in adjacent non-tumour epithelium in oral squamous cell carcinoma. Arch. Oral Biol. 97, 12–17 (2019).

Ramos‐García, P., Bravo, M., González‐Ruiz, L. & González‐Moles, M. Á. Significance of cytoplasmic cyclin D1 expression in oral oncogenesis. Oral Dis. 24, 98–102 (2018).

Jayasurya, R. et al. Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Mod. Pathol. 18, 1056–1066 (2005).

Ramos-Garcia, P. et al. Prognostic and clinicopathological significance of cyclin D1 expression in oral squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 83, 96–106 (2018).

Buchkovich, K., Duffy, L. A. & Harlow, E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58, 1097–1105 (1989).

Sun, W. et al. Activation of the NOTCH Pathway in Head and Neck CancerNOTCH in Head and Neck Cancer. Cancer Res. 74, 1091–1104 (2014).

Yap, L. F. et al. The opposing roles of NOTCH signalling in head and neck cancer: a mini review. Oral Dis. 21, 850–857 (2015).

Kałafut, J. et al. Shooting at moving and hidden targets—tumour cell plasticity and the notch signalling pathway in head and neck squamous cell carcinomas. Cancers 13, 6219 (2021).

Grilli, G. et al. Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma. Oral Oncol. 110, 105003 (2020).

D’assoro, A. B., Leon-Ferre, R., Braune, E.-B. & Lendahl, U. Roles of notch signaling in the tumor microenvironment. Int. J. Mol. Sci. 23, 6241 (2022).

Nowell, C. S. & Radtke, F. Notch as a tumour suppressor. Nat. Rev. Cancer 17, 145–159 (2017).

Ishida, T., Hijioka, H., Kume, K., Miyawaki, A. & Nakamura, N. Notch signaling induces EMT in OSCC cell lines in a hypoxic environment. Oncol. Lett. 6, 1201–1206 (2013).

Song, X. et al. Common and complex Notch1 mutations in chinese oral squamous cell carcinoma complexity of notch1 mutations in Chinese OSCC. Clin. Cancer Res. 20, 701–710 (2014).

Kwon, C. et al. Notch post-translationally regulates β-catenin protein in stem and progenitor cells. Nat. Cell Biol. 13, 1244–1251 (2011).

Lee, S. H. et al. Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma. Lab. Investig. 96, 508–516 (2016).

Nyman, P. E., Buehler, D. & Lambert, P. F. Loss of function of canonical notch signaling drives head and neck carcinogenesis effects of loss of function of Notch in HNSCC. Clin. Cancer Res. 24, 6308–6318 (2018).

Kozakiewicz, P. & Grzybowska‑Szatkowska, L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. Oncol. Lett. 15, 7497–7505 (2018).

Zhao, Y.-Y., Yu, G.-T., Xiao, T. & Hu, J. The Notch signaling pathway in head and neck squamous cell carcinoma: a meta-analysis. Adv. Clin. Exp. Med. 26, 881–887 (2017).

Castilho, R. M., Squarize, C. H. & Almeida, L. O. Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int. J. Mol. Sci. 18, 1506 (2017).

Hema, K. N., Smitha, T., Sheethal, H. S. & Mirnalini, S. A. Epigenetics in oral squamous cell carcinoma. J. Oral Maxillofac. Pathol. 21, 252 (2017).

Bais, M. V. Impact of epigenetic regulation on head and neck squamous cell carcinoma. J. Dent. Res. 98, 268–276 (2019).

D’Souza, W. & Saranath, D. Clinical implications of epigenetic regulation in oral cancer. Oral Oncol. 51, 1061–1068 (2015).

Irimie, A. I. et al. Current insights into oral cancer epigenetics. Int. J. Mol. Sci. 19, 670 (2018).

Goldberg, A. D., Allis, C. D. & Bernstein, E. Epigenetics: a landscape takes shape. Cell 128, 635–638 (2007).

Basu, B. et al. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India. Clin. Epigenet. 9, 1–15 (2017).

Guerrero-Preston, R. et al. Global DNA methylation: a common early event in oral cancer cases with exposure to environmental carcinogens or viral agents. P R Health Sci. J. 28, 24–29 (2009).

Supic, G., Kozomara, R., Jovic, N., Zeljic, K. & Magic, Z. Prognostic significance of tumor-related genes hypermethylation detected in cancer-free surgical margins of oral squamous cell carcinomas. Oral Oncol. 47, 702–708 (2011).

Towle, R. et al. Global analysis of DNA methylation changes during progression of oral cancer. Oral Oncol. 49, 1033–1042 (2013).

Gasche, J. A. & Goel, A. Epigenetic mechanisms in oral carcinogenesis. Fut. Oncol. 8, 1407–1425 (2012).

Feinberg, A. P. & Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89–92 (1983).

Feinberg, A. P. & Vogelstein, B. Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Commun. 111, 47–54 (1983).

Mascolo, M. et al. Epigenetic disregulation in oral cancer. Int. J. Mol. Sci. 13, 2331–2353 (2012).

Schussel, J. et al. EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions EDNRB and DCC methylation distinguish oral malignant lesion. Clin. Cancer Res. 19, 3268–3275 (2013).

Shaw, R. J. et al. Promoter methylation of P16, RARβ, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br. J. Cancer 94, 561–568 (2006).

Lin, R.-K. et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J. Clin. Investig. 120, 521–532 (2010).

Breitling, L. P., Yang, R., Korn, B., Burwinkel, B. & Brenner, H. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am. J. Hum. Genet. 88, 450–457 (2011).

Jayaprakash, C., Radhakrishnan, R., Ray, S. & Satyamoorthy, K. Promoter methylation of MGMT in oral carcinoma: A population-based study and meta-analysis. Arch. Oral Biol. 80, 197–208 (2017).

Guerrero-Preston, R. et al. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva differential methylation and oncogenic pathways in OSCC. Cancer Prev. Res. 4, 1061–1072 (2011).

Yeh, K.-T. et al. Epigenetic changes of tumor suppressor genes, P15, P16, VHL and P53 in oral cancer. Oncol. Rep. 10, 659–663 (2003).

Mendonsa, A. M., Na, T.-Y. & Gumbiner, B. M. E-cadherin in contact inhibition and cancer. Oncogene 37, 4769–4780 (2018).

Flanagan, D. J. et al. NOTUM from Apc-mutant cells biases clonal competition to initiate cancer. Nature 594, 430–435 (2021).

Repenning, A. et al. PRMT1 promotes the tumor suppressor function of p14ARF and is indicative for pancreatic cancer prognosis. EMBO J. 40, e106777 (2021).

Olesen, T. B. et al. Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 20, 145–158 (2019).

Du, F. et al. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. Cell Death Dis. 10, 1–10 (2019).

Khordadmehr, M., Shahbazi, R., Sadreddini, S. & Baradaran, B. miR‐193: a new weapon against cancer. J. Cell. Physiol. 234, 16861–16872 (2019).

Flausino, C. S., Daniel, F. I. & Modolo, F. DNA methylation in oral squamous cell carcinoma: from its role in carcinogenesis to potential inhibitor drugs. Crit. Rev. Oncol./Hematol. 164, 103399 (2021).

Nikitakis, N. G. et al. Molecular markers associated with development and progression of potentially premalignant oral epithelial lesions: Current knowledge and future implications. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 125, 650–669 (2018).

Daniel, F. I., Rivero, E. R. C., Modolo, F., Lopes, T. G. & Salum, F. G. Immunohistochemical expression of DNA methyltransferases 1, 3a and 3b in oral leukoplakias and squamous cell carcinomas. Arch. Oral Biol. 55, 1024–1030 (2010).

Baba, S. et al. Global DNA hypomethylation suppresses squamous carcinogenesis in the tongue and esophagus. Cancer Sci. 100, 1186–1191 (2009).

Supic, G., Kozomara, R., Zeljic, K., Jovic, N. & Magic, Z. Prognostic value of the DNMTs mRNA expression and genetic polymorphisms on the clinical outcome in oral cancer patients. Clin. Oral Investig. 21, 173–182 (2017).

Seitz, H. K. & Stickel, F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat. Rev. Cancer 7, 599–612 (2007).

Wu, C.-S. et al. ASC contributes to metastasis of oral cavity squamous cell carcinoma. Oncotarget 7, 50074 (2016).

Ling, Y. et al. Roles of CEACAM1 in cell communication and signaling of lung cancer and other diseases. Cancer Metastasis Rev. 34, 347–357 (2015).

Wu, B., Xiong, X., Jia, J. & Zhang, W.-F. MicroRNAs: new actors in the oral cancer scene. Oral Oncol. 47, 314–319 (2011).

Facompre, N. D., Harmeyer, K. H. & Basu, D. Regulation of oncogenic PI3-kinase signaling by JARID1B. Oncotarget 8, 7218 (2017).

Urosevic, J. et al. Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat. Cell Biol. 16, 685–694 (2014).

Li, Y. & Seto, E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb. Perspect. Med. 6, a026831 (2016).

Almeida, L. O. et al. NFκB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC). FEBS Open Bio. 4, 96–104 (2014).

Almeida, L. O. et al. Unlocking the chromatin of adenoid cystic carcinomas using HDAC inhibitors sensitize cancer stem cells to cisplatin and induces tumor senescence. Stem Cell Res. 21, 94–105 (2017).

Guimarães, D. M. et al. Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells. Oncotarget 7, 42447 (2016).

Webber, L. P. et al. Hypoacetylation of acetyl‐histone H3 (H3K9ac) as marker of poor prognosis in oral cancer. Histopathology 71, 278–286 (2017).

Chen, Y.-W., Kao, S.-Y., Wang, H.-J. & Yang, M.-H. Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma. Cancer 119, 4259–4267 (2013).

Witt, O., Deubzer, H. E., Milde, T. & Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett. 277, 8–21 (2009).

Rastogi, B. et al. Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis. Mol. Cell. Biochem. 415, 183–196 (2016).

Kumar, B., Yadav, A., Lang, J. C., Teknos, T. N. & Kumar, P. Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog. Genes Cancer 6, 169 (2015).

Chang, H.-H. et al. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 45, 610–614 (2009).

Kumar, R., Li, D.-Q., Müller, S. & Knapp, S. Epigenomic regulation of oncogenesis by chromatin remodeling. Oncogene 35, 4423–4436 (2016).

Panchal, O. et al. SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC). Sci. Rep. 10, 1–13 (2020).

Vitale, I., Manic, G., Maria, R., de, Kroemer, G. & Galluzzi, L. DNA damage in stem cells. Mol. Cell 66, 306–319 (2017).

Hung, M. H. et al. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nat. Commun. 12, 1–15 (2021).

Aydin, Ö. Z., Vermeulen, W. & Lans, H. ISWI chromatin remodeling complexes in the DNA damage response. Cell Cycle 13, 3016–3025 (2014).

Fang, F.-M. et al. Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am. J. Pathol. 178, 2407–2415 (2011).

D’ANGELO, B., Benedetti, E., Cimini, A. & Giordano, A. MicroRNAs: a puzzling tool in cancer diagnostics and therapy. Anticancer Res. 36, 5571–5575 (2016).

Deng, M. et al. TET-mediated sequestration of miR-26 drives EZH2 expression and gastric carcinogenesis. Cancer Res. 77, 6069–6082 (2017).

Zhang, W. et al. miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. Lab. Investig. 98, 1397–1407 (2018).

Viticchiè, G. et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 10, 1121–1131 (2011).

Jia, L.-F. et al. miR-29b suppresses proliferation, migration, and invasion of tongue squamous cell carcinoma through PTEN–AKT signaling pathway by targeting Sp1. Oral Oncol. 50, 1062–1071 (2014).

Esquela-Kerscher, A. & Slack, F. J. Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259–269 (2006).

Kanlikilicer, P. et al. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine 38, 100–112 (2018).

Sakha, S., Muramatsu, T., Ueda, K. & Inazawa, J. Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma. Sci. Rep. 6, 1–11 (2016).

Liu, C.-J. et al. Increase of microRNA miR‐31 level in plasma could be a potential marker of oral cancer. Oral Dis. 16, 360–364 (2010).

Liu, C.-J., Lin, S.-C., Yang, C.-C., Cheng, H.-W. & Chang, K.-W. Exploiting salivary miR‐31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 34, 219–224 (2012).

Rezaei, T. et al. microRNA-181 serves as a dual-role regulator in the development of human cancers. Free Radic. Biol. Med. 152, 432–454 (2020).

Shin, K.-H. et al. miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem. Biophys. Res. Commun. 404, 896–902 (2011).

Chang, C.-C. et al. MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral Oncol. 49, 923–931 (2013).

Chen, Y.-F. et al. MicroRNA-211 enhances the oncogenicity of carcinogen-induced oral carcinoma by repressing TCF12 and increasing antioxidant activity miR-211-TCF12-FAM213A activation in OSCC. Cancer Res. 76, 4872–4886 (2016).

Ayers, D. & Vandesompele, J. Influence of microRNAs and long non-coding RNAs in cancer chemoresistance. Genes 8, 95 (2017).

Hebert, C., Norris, K., Scheper, M. A., Nikitakis, N. & Sauk, J. J. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol. Cancer 6, 1–11 (2007).

Sun, L. et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 31, 432–445 (2012).

Chen, Q., Qin, R., Fang, Y. & Li, H. Berberine sensitizes human ovarian cancer cells to cisplatin through miR-93/PTEN/Akt signaling pathway. Cell. Physiol. Biochem. 36, 956–965 (2015).

Komatsu, S. et al. Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma. Oncotarget 7, 62034 (2016).

Meng, X. et al. The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun. 41, 981–1006 (2021).

Liu, J. et al. ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression. Cancer Cell Int. 22, 1–14 (2022).

Yeh, L.-Y., Chou, C.-H., Liu, C.-J., Lin, S.-C. & Chang, K.-W. miR-372 enhances tumorigenesis and drug resistance in oral carcinoma by targeting ZBTB7A transcription factor. Cancer Res. 78, 479 (2018).

Feller, L., Altini, M. & Lemmer, J. Inflammation in the context of oral cancer. Oral Oncol. 49, 887–892 (2013).

Niu, X., Yang, B., Liu, F. & Fang, Q. LncRNA HOXA11-AS promotes OSCC progression by sponging miR-98-5p to upregulate YBX2 expression. Biomed. Pharmacother. 121, 109623 (2020).

Xu, C., He, T., Li, Z., Liu, H. & Ding, B. Regulation of HOXA11-AS/miR-214-3p/EZH2 axis on the growth, migration and invasion of glioma cells. Biomed. Pharmacother. 95, 1504–1513 (2017).

Geng, Y., Jiang, J. & Wu, C. Function and clinical significance of circRNAs in solid tumors. J. Hematol. Oncol. 11, 1–20 (2018).

Chatterjee, R. et al. Pathophysiological relationship between hypoxia associated oxidative stress, Epithelial-mesenchymal transition, stemness acquisition and alteration of Shh/Gli-1 axis during oral sub-mucous fibrosis and oral squamous cell carcinoma. Eur. J. Cell Biol. 100, 151146 (2021).

Li, Z. et al. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Mol. Oncol. 9, 1091–1105 (2015).

Biddle, A., Gammon, L., Liang, X., Costea, D. E. & Mackenzie, I. C. Phenotypic plasticity determines cancer stem cell therapeutic resistance in oral squamous cell carcinoma. EBioMedicine 4, 138–145 (2016).

Vig, N., Mackenzie, I. C. & Biddle, A. Phenotypic plasticity and epithelial‐to‐mesenchymal transition in the behaviour and therapeutic response of oral squamous cell carcinoma. J. Oral Pathol. Med. 44, 649–655 (2015).

Liu, S., Liu, D., Li, J., Zhang, D. & Chen, Q. Regulatory T cells in oral squamous cell carcinoma. J. Oral Pathol. Med. 45, 635–639 (2016).

Gaur, P., Singh, A. K., Shukla, N. K. & Das, S. N. Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance. Hum. Immunol. 75, 330–337 (2014).

Schwarz, S., Butz, M., Morsczeck, C., Reichert, T. E. & Driemel, O. Increased number of CD25+ FoxP3+ regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining. J. Oral Pathol. Med. 37, 485–489 (2008).

Duray, A., Demoulin, S., Hubert, P., Delvenne, P. & Saussez, S. Immune suppression in head and neck cancers: a review. Clin. Dev. Immunol. 2010, 701657 (2010).

Sathiyasekar, A. C., Chandrasekar, P., Pakash, A., Kumar, K. G. & Jaishlal, M. S. Overview of immunology of oral squamous cell carcinoma. J. Pharm. Bioallied Sci. 8, S8 (2016).

Caponio, V. C. A., Zhurakivska, K., Lo Muzio, L., Troiano, G. & Cirillo, N. The immune cells in the development of oral squamous cell carcinoma. Cancers 15, 3779 (2023).

de Ruiter, E. J., Ooft, M. L., Devriese, L. A. & Willems, S. M. The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Oncoimmunology 6, e1356148 (2017).

Zitvogel, L. & Kroemer, G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1, 1223–1225 (2012).

Alsahafi, E. et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis. 10, 1–17 (2019).

Lythgoe, M. P., Liu, D. S. K., Annels, N. E., Krell, J. & Frampton, A. E. Gene of the month: Lymphocyte-activation gene 3 (LAG-3). J. Clin. Pathol. 74, 543–547 (2021).

Zhou, K. et al. Immunosuppression of human adipose-derived stem cells on T cell subsets via the reduction of NF-kappaB activation mediated by PD-L1/PD-1 and Gal-9/TIM-3 pathways. Stem Cells Dev. 27, 1191–1202 (2018).

Zhou, X. et al. The novel non‐immunological role and underlying mechanisms of B7‐H3 in tumorigenesis. J. Cell. Physiol. 234, 21785–21795 (2019).

Davis, R. J., van Waes, C. & Allen, C. T. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 58, 59–70 (2016).

Wolf, G. T. et al. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck 33, 1666–1674 (2011).

Furquim, C. P., Pivovar, A., Amenábar, J. M., Bonfim, C. & Torres-Pereira, C. C. Oral cancer in Fanconi anemia: Review of 121 cases. Crit. Rev. Oncol./Hematol. 125, 35–40 (2018).

Alter, B. P. et al. Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: a search for human papillomavirus. Int. J. Cancer 133, 1513–1515 (2013).

Amenábar, J. M., Torres‐Pereira, C. C., Tang, K. D. & Punyadeera, C. Two enemies, one fight: an update of oral cancer in patients with Fanconi anemia. Cancer 125, 3936–3946 (2019).

Bongiorno, M., Rivard, S., Hammer, D. & Kentosh, J. Malignant transformation of oral leukoplakia in a patient with dyskeratosis congenita. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 124, e239–e242 (2017).

Horton, J. D., Knochelmann, H. M., Day, T. A., Paulos, C. M. & Neskey, D. M. Immune evasion by head and neck cancer: foundations for combination therapy. Trends Cancer 5, 208–232 (2019).

Wang, L. et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway. Oncotarget 8, 76116 (2017).

Zhang, D. et al. Cancer‐associated fibroblasts promote tumor progression by lncRNA‐mediated RUNX2/GDF10 signaling in oral squamous cell carcinoma. Mol. Oncol. 16, 780–794 (2022).

Prime, S. S. et al. Fibroblast activation and senescence in oral cancer. J. Oral Pathol. Med. 46, 82–88 (2017).

Tan, M. L., Parkinson, E. K., Yap, L. F. & Paterson, I. C. Autophagy is deregulated in cancer-associated fibroblasts from oral cancer and is stimulated during the induction of fibroblast senescence by TGF-β1. Sci. Rep. 11, 584 (2021).

Hassona, Y., Cirillo, N., Heesom, K., Parkinson, E. K. & Prime, S. S. Senescent cancer-associated fibroblasts secrete active MMP-2 that promotes keratinocyte dis-cohesion and invasion. Br. J. Cancer 111, 1230–1237 (2014).

Bijai, L. K. & Muthukrishnan, A. Potential role of fibroblast senescence in malignant transformation of oral submucous fibrosis. Oral Oncol. 127, 105810 (2022).

Kim, E. K., Moon, S., Kim, D. K., Zhang, X. & Kim, J. CXCL1 induces senescence of cancer-associated fibroblasts via autocrine loops in oral squamous cell carcinoma. PLoS ONE 13, e0188847 (2018).

Lu, Y. et al. Peroxiredoxin1 knockdown inhibits oral carcinogenesis via inducing cell senescence dependent on mitophagy. OncoTargets Ther. 14, 239–251 (2021).

Chen, Y. et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J. Biomed. Sci. 26, 1–13 (2019).

Yang, Q. et al. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharmaceut. Sin. B 10, 2156–2170 (2020).

Goswami, K. K. et al. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Cell. Immunol. 316, 1–10 (2017).

Jiang, C., Yuan, F., Wang, J. & Wu, L. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. Immunobiology 222, 651–657 (2017).

Zhu, Y. et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models CSF1R blockade improves checkpoint immunotherapy. Cancer Res. 74, 5057–5069 (2014).

Chen, J. et al. Suppression of T cells by myeloid-derived suppressor cells in cancer. Hum. Immunol. 78, 113–119 (2017).

Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 19, 108–119 (2018).

Groth, C. et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer 120, 16–25 (2019).

Qu, P., Wang, L. & Lin, P. C. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Lett. 380, 253–256 (2016).

Pyzer, A. R., Cole, L., Rosenblatt, J. & Avigan, D. E. Myeloid‐derived suppressor cells as effectors of immune suppression in cancer. Int. J. Cancer 139, 1915–1926 (2016).

Aggarwal, S., Sharma, S. C. & N Das, S. Dynamics of regulatory T cells (Tregs) in patients with oral squamous cell carcinoma. J. Surg. Oncol. 116, 1103–1113 (2017).

Munn, D. H. & Bronte, V. Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39, 1–6 (2016).

Ni, X. et al. YAP is essential for treg-mediated suppression of antitumor immunity. Cancer Discov. 8, 1026–1043 (2018).

Meng, X. et al. Regulatory T cells in cardiovascular diseases. Nat. Rev. Cardiol. 13, 167–179 (2016).

Miyara, M. & Sakaguchi, S. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 13, 108–116 (2007).

Ohue, Y. & Nishikawa, H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci. 110, 2080–2089 (2019).

Li, C., Jiang, P., Wei, S., Xu, X. & Wang, J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol. Cancer 19, 1–23 (2020).

Fuse, H. et al. Enhanced expression of PD-L1 in oral squamous cell carcinoma-derived CD11b+ Gr-1+ cells and its contribution to immunosuppressive activity. Oral Oncol. 59, 20–29 (2016).

Wynn, T. A. Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 15, 271–282 (2015).

Joseph, J. P., Harishankar, M. K., Pillai, A. A. & Devi, A. Hypoxia induced EMT: a review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncol. 80, 23–32 (2018).

Kumar, A. & Deep, G. Hypoxia in tumor microenvironment regulates exosome biogenesis: Molecular mechanisms and translational opportunities. Cancer Lett. 479, 23–30 (2020).

Muz, B., de La Puente, P., Azab, F. & Kareem Azab, A. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 3, 83–92 (2015).

Bhandari, V. et al. Molecular landmarks of tumor hypoxia across cancer types. Nat. Genet. 51, 308–318 (2019).

Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 364, 656–665 (2011).

Pérez-Sayáns, M. et al. Hypoxia-inducible factors in OSCC. Cancer Lett. 313, 1–8 (2011).

Lipkowitz, S. & Weissman, A. M. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer 11, 629–643 (2011).

Corn, P. G., McDonald, E. R., Herman, J. G. & El-Deiry, W. S. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel–Lindau protein. Nat. Genet. 35, 229–237 (2003).

Greer, S. N., Metcalf, J. L., Wang, Y. & Ohh, M. The updated biology of hypoxia‐inducible factor. EMBO J. 31, 2448–2460 (2012).

Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F. & Maity, A. Regulation of glut1 mRNA by hypoxia-inducible factor-1: interaction between H-ras and hypoxia. J. Biol. Chem. 276, 9519–9525 (2001).

Gammon, L. & Mackenzie, I. C. Roles of hypoxia, stem cells and epithelial–mesenchymal transition in the spread and treatment resistance of head and neck cancer. J. Oral Pathol. Med. 45, 77–82 (2016).

Koukourakis, M. I. et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin. Cancer Res. 7, 3399–3403 (2001).

Tsai, Y.-P. & Wu, K.-J. Hypoxia-regulated target genes implicated in tumor metastasis. J. Biomed. Sci. 19, 1–7 (2012).

Duan, Y. et al. Hypoxia induced Bcl-2/Twist1 complex promotes tumor cell invasion in oral squamous cell carcinoma. Oncotarget 8, 7729 (2017).

Amelio, I. et al. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc. Natl Acad. Sci. USA 115, E10869–E10878 (2018).

Amelio, I. & Melino, G. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. Trends Biochem. Sci. 40, 425–434 (2015).

Domingos, P. L. B. et al. Hypoxia reduces the E-cadherin expression and increases OSCC cell migration regardless of the E-cadherin methylation profile. Pathol. Res. Pract. 213, 496–501 (2017).

Qin, Q., Xu, Y., He, T., Qin, C. & Xu, J. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 22, 90–106 (2012).

Zheng, Y., Ni, Y., Huang, X., Wang, Z. & Han, W. E. Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis. Oncol. Lett. 5, 1285–1289 (2013).

Xie, L. et al. Association between dietary nitrate and nitrite intake and site-specific cancer risk: evidence from observational studies. Oncotarget 7, 56915 (2016).

Nair, U., Bartsch, H. & Nair, J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis 19, 251–262 (2004).

Jing, X. et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer 18, 1–15 (2019).

Banerjee, S. et al. Microbial signatures associated with oropharyngeal and oral squamous cell carcinomas. Sci. Rep. 7, 1–20 (2017).

Perera, M., Al-Hebshi, N. N., Speicher, D. J., Perera, I. & Johnson, N. W. Emerging role of bacteria in oral carcinogenesis: a review with special reference to perio-pathogenic bacteria. J. Oral Microbiol. 8, 32762 (2016).

Irfan, M., Delgado, R. Z. R. & Frias-Lopez, J. The oral microbiome and cancer. Front. Immunol. 11, 591088 (2020).

Yost, S. et al. Increased virulence of the oral microbiome in oral squamous cell carcinoma revealed by metatranscriptome analyses. Int. J. Oral Sci. 10, 32 (2018).

Eun, Y.-G. et al. Oral microbiome associated with lymph node metastasis in oral squamous cell carcinoma. Sci. Rep. 11, 23176 (2021).

Rizzetto, L., de Filippo, C. & Cavalieri, D. Richness and diversity of mammalian fungal communities shape innate and adaptive immunity in health and disease. Eur. J. Immunol. 44, 3166–3181 (2014).

Deo, P. N. & Deshmukh, R. Oral microbiome: Unveiling the fundamentals. J. Oral Maxillofac. Pathol. 23, 122 (2019).

Mosaddad, S. A. et al. Oral microbial biofilms: an update. Eur. J. Clin. Microbiol. Infect. Dis. 38, 2005–2019 (2019).

Willis, J. R. & Gabaldón, T. The human oral microbiome in health and disease: from sequences to ecosystems. Microorganisms 8, 308 (2020).

Idris, A., Hasnain, S. Z., Huat, L. Z. & Koh, D. Human diseases, immunity and the oral microbiota—Insights gained from metagenomic studies. Oral Sci. Int. 14, 27–32 (2017).

Li, Q. et al. Role of oral bacteria in the development of oral squamous cell carcinoma. Cancers 12, 2797 (2020).

Mao, W.-M., Zheng, W.-H. & Ling, Z.-Q. Epidemiologic risk factors for esophageal cancer development. Asian Pac. J. Cancer Prev. 12, 2461–2466 (2011).

Wang, H. et al. Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas. Genome Med. 9, 1–10 (2017).

Gholizadeh, P. et al. Role of oral microbiome on oral cancers, a review. Biomed. Pharmacother. 84, 552–558 (2016).

Frank, D. N. et al. A dysbiotic microbiome promotes head and neck squamous cell carcinoma. Oncogene 41, 1269–1280 (2022).

Mager, D. L. et al. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J. Transl. Med. 3, 1–8 (2005).

Yang, K. et al. Oral microbiota analysis of tissue pairs and saliva samples from patients with oral squamous cell carcinoma–a pilot study. Front. Microbiol. 12, 719601 (2021).

Delaney, C. et al. Limitations of using 16S rRNA microbiome sequencing to predict oral squamous cell carcinoma. APMIS 131, 262–276 (2023).

Hashimoto, K. et al. Feasibility of oral microbiome profiles associated with oral squamous cell carcinoma. J. Oral Microbiol. 14, 2105574 (2022).

Groeger, S., Domann, E., Gonzales, J. R., Chakraborty, T. & Meyle, J. B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis. Immunobiology 216, 1302–1310 (2011).

Lafuente Ibáñez de Mendoza, I., Maritxalar Mendia, X., Garcia de la Fuente, A. M., Quindos Andres, G. & Aguirre Urizar, J. M. Role of Porphyromonas gingivalis in oral squamous cell carcinoma development: a systematic review. J. Periodontal. Res. 55, 13–22 (2020).

Börnigen, D. et al. Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer. Sci. Rep. 7, 1–13 (2017).

Marttila, E. et al. Acetaldehyde production and microbial colonization in oral squamous cell carcinoma and oral lichenoid disease. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 116, 61–68 (2013).

Kurkivuori, J. et al. Acetaldehyde production from ethanol by oral streptococci. Oral Oncol. 43, 181–186 (2007).

Rautemaa, R., Hietanen, J., Niissalo, S., Pirinen, S. & Perheentupa, J. Oral and oesophageal squamous cell carcinoma–a complication or component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I). Oral Oncol. 43, 607–613 (2007).

Solis, N. V., Swidergall, M., Bruno, V. M., Gaffen, S. L. & Filler, S. G. The aryl hydrocarbon receptor governs epithelial cell invasion during oropharyngeal candidiasis. MBio 8, e00025–17 (2017).

Zhu, W. et al. EGFR and HER2 receptor kinase signaling mediate epithelial cell invasion by Candida albicans during oropharyngeal infection. Proc. Natl Acad. Sci. USA 109, 14194–14199 (2012).

Warnakulasuriya, S. & Ariyawardana, A. Malignant transformation of oral leukoplakia: a systematic review of observational studies. J. Oral Pathol. Med. 45, 155–166 (2016).

Nadeau, C. & Kerr, A. R. Evaluation and management of oral potentially malignant disorders. Dent. Clin. 62, 1–27 (2018).

Monteiro, L. et al. Type of surgical treatment and recurrence of oral leukoplakia: a retrospective clinical study. Med. Oral Patol. Oral Cir. Bucal. 22, e520 (2017).

Brignardello-Petersen, R. Proliferative verrucous leukoplakia and erythroplakia are probably the disorders with the highest rate of malignant transformation. J. Am. Dent. Assoc. 151, e62 (2020).

van der Waal, I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 45, 317–323 (2009).

Armstrong, W. B. et al. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol. Biomark. Prev. 9, 43–47 (2000).

Armstrong, W. B. et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase Ⅱa chemoprevention trial. Clin. Cancer Res. 6, 4684–4691 (2000).

Chaudhry, Z., Gupta, S. R. & Oberoi, S. S. The efficacy of ErCr: YSGG laser fibrotomy in management of moderate oral submucous fibrosis: a preliminary study. J. Maxillofac. Oral Surg. 13, 286–294 (2014).

Shah, P. H., Venkatesh, R., More, C. B. & Vassandacoumara, V. Comparison of therapeutic efficacy of placental extract with dexamethasone and hyaluronic acid with dexamethasone for oral submucous fibrosis-a retrospective analysis. J. Clin. Diagn. Res. 10, ZC63 (2016).

Cheng, Y.-S. L., Gould, A., Kurago, Z., Fantasia, J. & Muller, S. Diagnosis of oral lichen planus: a position paper of the American Academy of Oral and Maxillofacial Pathology. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 122, 332–354 (2016).

Liu, C. et al. Efficacy of intralesional betamethasone for erosive oral lichen planus and evaluation of recurrence: a randomized, controlled trial. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 116, 584–590 (2013).

Olson, M. A., Rogers, R. S. Ⅲ & Bruce, A. J. Oral lichen planus. Clin. Dermatol. 34, 495–504 (2016).

Halonen, P. et al. Cancer risk of Lichen planus: a cohort study of 13,100 women in Finland. Int. J. Cancer 142, 18–22 (2018).

Sutton, D. N., Brown, J. S., Rogers, S. N., Vaughan, E. D. & Woolgar, J. A. The prognostic implications of the surgical margin in oral squamous cell carcinoma. Int. J. Oral Maxillofac. Surg. 32, 30–34 (2003).

Brands, M. T., Brennan, P. A., Verbeek, A. L., Merkx, M. A. & Geurts, S. M. Follow-up after curative treatment for oral squamous cell carcinoma. A critical appraisal of the guidelines and a review of the literature. Eur. J. Surg. Oncol. 44, 559–565 (2018).

Mistry, R. C., Qureshi, S. S. & Kumaran, C. Post‐resection mucosal margin shrinkage in oral cancer: quantification and significance. J. Surg. Oncol. 91, 131–133 (2005).

Petruzzi, M., Lucchese, A., Baldoni, E., Grassi, F. R. & Serpico, R. Use of Lugol’s iodine in oral cancer diagnosis: an overview. Oral Oncol. 46, 811–813 (2010).

Xiao, T., Kurita, H., Shimane, T., Nakanishi, Y. & Koike, T. Vital staining with iodine solution in oral cancer: iodine infiltration, cell proliferation, and glucose transporter 1. Int. J. Clin. Oncol. 18, 792–800 (2013).

Sakuraba, M. et al. Recent advances in reconstructive surgery: head and neck reconstruction. Int. J. Clin. Oncol. 18, 561–565 (2013).

Tsao, A. S. et al. Phase Ⅱ randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev. Res. 2, 931–941 (2009).

Furusaka, T., Asakawa, T., Tanaka, A., Matsuda, H. & Ikeda, M. Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer. Acta Otolaryngol. 132, 1108–1114 (2012).

Mitsudo, K. et al. Organ preservation with daily concurrent chemoradiotherapy using superselective intra-arterial infusion via a superficial temporal artery for T3 and T4 head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 79, 1428–1435 (2011).

Colli, L. M. et al. Landscape of combination immunotherapy and targeted therapy to improve cancer management prioritizing immunotherapy and targeted drug combinations. Cancer Res. 77, 3666–3671 (2017).

Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116–1127 (2008).

Yu, C.-C. et al. Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo. Oncotarget 8, 68641 (2017).

Xu, J., Wu, Z. & Huang, J. Flavopereirine suppresses the progression of human oral cancer by inhibiting the JAK-STAT signaling pathway via targeting LASP1. Drug Des. Dev. Ther. 15, 1705 (2021).

Gan, R. et al. FLI-06 intercepts notch signaling and suppresses the proliferation and self-renewal of tongue cancer cells. OncoTargets Ther. 12, 7663 (2019).

Smith, D. C. et al. First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase Ⅰ study for patients with advanced solid tumors. J. Clin. Oncol. 31, 2540–2540 (2013).

Liu, J. et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl Acad. Sci. USA 110, 20224–20229 (2013).

Brahmer, J. R. et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).

Burtness, B. et al. KEYNOTE-048: Phase Ⅲ study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ann. Oncol. 29, viii729 (2018).

Cohen, E. E. W. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393, 156–167 (2019).

Burova, E. et al. Preclinical development of the anti-LAG-3 antibody REGN3767: Characterization and activity in combination with the anti-PD-1 antibody cemiplimab in human PD-1xLAG-3–knockin mice. Mol. Cancer Therapeut. 18, 2051–2062 (2019).

Huang, J., Barbera, L., Brouwers, M., Browman, G. & Mackillop, W. J. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J. Clin. Oncol. 21, 555–563 (2003).

Lee, W.-H. S. et al. Effective killing of acute myeloid leukemia by TIM-3 targeted chimeric antigen receptor T CellsmRNA encoding anti–TIM-3 CAR T cells to treat AML. Mol. Cancer Therapeut. 20, 1702–1712 (2021).

Maeda, S., Murakami, K., Inoue, A., Yonezawa, T. & Matsuki, N. CCR4 blockade depletes regulatory T cells and prolongs survival in a canine model of bladder cancer anti-treg immunotherapy for canine bladder cancer. Cancer Immunol. Res. 7, 1175–1187 (2019).

Fultang, L. et al. MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine 47, 235–246 (2019).

Wolf, G. T. et al. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. Oral Oncol. 111, 104928 (2020).

Yete, S. & Saranath, D. MicroRNAs in oral cancer: biomarkers with clinical potential. Oral Oncol. 110, 105002 (2020).

Zanoni, D. K. et al. Survival outcomes after treatment of cancer of the oral cavity (1985–2015). Oral Oncol. 90, 115–121 (2019).

Almangush, A. et al. Staging and grading of oral squamous cell carcinoma: an update. Oral Oncol. 107, 104799 (2020).

Rivera, C., Oliveira, A. K., Costa, R. A. P., Rossi, Tde & Leme, A. F. P. Prognostic biomarkers in oral squamous cell carcinoma: a systematic review. Oral Oncol. 72, 38–47 (2017).

Sasahira, T. & Kirita, T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma. Int. J. Mol. Sci. 19, 2413 (2018).

Suresh, G. M., Koppad, R., Prakash, B. V., Sabitha, K. S. & Dhara, P. S. Prognostic indicators of oral squamous cell carcinoma. Ann. Maxillofac. Surg. 9, 364 (2019).

Kather, J. N. et al. Continuous representation of tumor microvessel density and detection of angiogenic hotspots in histological whole-slide images. Oncotarget 6, 19163 (2015).

Mărgăritescu, C. et al. VEGF expression and angiogenesis in oral squamous cell carcinoma: an immunohistochemical and morphometric study. Clin. Exp. Med. 10, 209–214 (2010).

Sakata, J. et al. HMGA2 contributes to distant metastasis and poor prognosis by promoting angiogenesis in oral squamous cell carcinoma. Int. J. Mol. Sci. 20, 2473 (2019).

Dong, Z. et al. Overexpression of Id-1 is associated with tumor angiogenesis and poor clinical outcome in oral squamous cell carcinoma. Oral Oncol. 46, 154–157 (2010).

Hong, K.-O. et al. Tumor budding is associated with poor prognosis of oral squamous cell carcinoma and histologically represents an epithelial-mesenchymal transition process. Hum. Pathol. 80, 123–129 (2018).

Almangush, A. et al. Tumour budding in oral squamous cell carcinoma: a meta-analysis. Br. J. Cancer 118, 577–586 (2018).

Staton, C. A., Reed, M. W. R. & Brown, N. J. A critical analysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol. 90, 195–221 (2009).

Seki, M., Sano, T., Yokoo, S. & Oyama, T. Tumour budding evaluated in biopsy specimens is a useful predictor of prognosis in patients with cN0 early stage oral squamous cell carcinoma. Histopathology 70, 869–879 (2017).

Alkhadar, H., Macluskey, M., White, S. & Ellis, I. Perineural invasion in oral squamous cell carcinoma: Incidence, prognostic impact and molecular insight. J. Oral Pathol. Med. 49, 994–1003 (2020).

Yu, E.-H., Tu, H.-F., Wu, C.-H., Yang, C.-C. & Chang, K.-W. MicroRNA-21 promotes perineural invasion and impacts survival in patients with oral carcinoma. J. Chin. Med. Assoc. 80, 383–388 (2017).

Tassone, P. et al. The role of matrixmetalloproteinase-2 expression by fibroblasts in perineural invasion by oral cavity squamous cell carcinoma. Oral Oncol. 132, 106002 (2022).

Zollo, M. et al. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin. Exp. Metastasis 29, 585–601 (2012).

Rylands, J., Lowe, D. & Rogers, S. N. Outcomes by area of residence deprivation in a cohort of oral cancer patients: survival, health-related quality of life, and place of death. Oral Oncol. 52, 30–36 (2016).

Liu, F. et al. Prospective study on factors affecting the prognosis of oral cancer in a Chinese population. Oncotarget 8, 4352 (2017).

Lambert, R., Sauvaget, C., Camargo Cancela, Mde & Sankaranarayanan, R. Epidemiology of cancer from the oral cavity and oropharynx. Eur. J. Gastroenterol. Hepatol. 23, 633–641 (2011).

Jayaprakash, V. et al. Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985–2010. Oral Oncol. 47, 1048–1054 (2011).

Ramqvist, T. et al. Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters. Oral Oncol. 51, 1126–1131 (2015).

Sousa, L. Gde et al. Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. Oral Oncol. 138, 106311 (2023).

Fakhry, C. & D’Souza, G. Discussing the diagnosis of HPV-OSCC: Common questions and answers. Oral Oncol. 49, 863–871 (2013).

Wang, F. et al. A systematic investigation of the association between HPV and the clinicopathological parameters and prognosis of oral and oropharyngeal squamous cell carcinomas. Cancer Med. 6, 910–917 (2017).

Xiao, W. et al. Circular RNAs in cell cycle regulation: mechanisms to clinical significance. Cell Prolif. 54, e13143 (2021).

Hu, X., Xia, K., Xiong, H. & Su, T. G3BP1 may serve as a potential biomarker of proliferation, apoptosis, and prognosis in oral squamous cell carcinoma. J. Oral Pathol. Med. 50, 995–1004 (2021).

Wang, J. et al. The prognostic value of B7‐H6 protein expression in human oral squamous cell carcinoma. J. Oral Pathol. Med. 46, 766–772 (2017).

Wu, C.-C. et al. Overexpression of FAM3C is associated with poor prognosis in oral squamous cell carcinoma. Pathol. Res. Pract. 215, 772–778 (2019).

Yu, V. et al. Electronic cigarettes induce DNA strand breaks and cell death independently of nicotine in cell lines. Oral Oncol. 52, 58–65 (2016).

Hawk, E. T. & Colbert Maresso, K. E-Cigarettes: unstandardized, under-regulated, understudied, and unknown health and cancer risks e-cigarettes: unknown health and cancer risks. Cancer Res. 79, 6079–6083 (2019).

Reidy, J., McHugh, E. & Stassen, L. F. A review of the relationship between alcohol and oral cancer. Surgeon 9, 278–283 (2011).

Madathil, S. A. et al. Nonlinear association between betel quid chewing and oral cancer: Implications for prevention. Oral Oncol. 60, 25–31 (2016).

Chaturvedi, A. K. et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J. Clin. Oncol. 36, 262 (2018).

Sathish, N., Wang, X. & Yuan, Y. Human papillomavirus (HPV)-associated oral cancers and treatment strategies. J. Dent. Res. 93, 29S–36S (2014).

Hübbers, C. U. & Akgül, B. HPV and cancer of the oral cavity. Virulence 6, 244–248 (2015).

Gondivkar, S. M. et al. Involvement of viral factors with head and neck cancers. Oral Oncol. 48, 195–199 (2012).

de La Cour, C. D., Sperling, C. D., Belmonte, F., Syrjänen, S. & Kjaer, S. K. Human papillomavirus prevalence in oral potentially malignant disorders: systematic review and meta‐analysis. Oral Dis. 27, 431–438 (2021).

Vogtmann, E. & Goedert, J. J. Epidemiologic studies of the human microbiome and cancer. Br. J. Cancer 114, 237–242 (2016).

Farah, C. S. et al. Oral cancer and oral potentially malignant disorders. Int. J. Dent. 2014, 853479 (2014).

Hu, Q. et al. Obesity and genes related to lipid metabolism predict poor survival in oral squamous cell carcinoma. Oral Oncol. 89, 14–22 (2019).

Sinevici, N. & O’sullivan, J. Oral cancer: deregulated molecular events and their use as biomarkers. Oral Oncol. 61, 12–18 (2016).

Dumache, R. Early diagnosis of oral squamous cell carcinoma by salivary microRNAs. Clin. Lab. 63, 1771–1776 (2017).

Dikova, V., Jantus-Lewintre, E. & Bagan, J. Potential non-invasive biomarkers for early diagnosis of oral squamous cell carcinoma. J. Clin. Med. 10, 1658 (2021).

Bolandparva, F. et al. Early diagnosis of oral squamous cell carcinoma (OSCC) by miR-138 and miR-424-5p expression as a cancer marker. Asian Pac. J. Cancer Prev. 22, 2185 (2021).

Sujir, N., Ahmed, J., Pai, K., Denny, C. & Shenoy, N. Challenges in early diagnosis of oral cancer: Cases series. Acta Stomatol. Croat. 53, 174 (2019).

Roi, A. et al. The challenges of OSCC diagnosis: salivary cytokines as potential biomarkers. J. Clin. Med. 9, 2866 (2020).

Lingen, M. W., Kalmar, J. R., Karrison, T. & Speight, P. M. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 44, 10–22 (2008).

Carreras-Torras, C. & Gay-Escoda, C. Techniques for early diagnosis of oral squamous cell carcinoma: Systematic review. Med. Oral Patol. Oral Cir. Bucal. 20, e305 (2015).

Javaid, M. A., Ahmed, A. S., Durand, R. & Tran, S. D. Saliva as a diagnostic tool for oral and systemic diseases. J. Oral Biol. Craniofacial. Res. 6, 67–76 (2016).

McKinney, S. M. et al. International evaluation of an AI system for breast cancer screening. Nature 577, 89–94 (2020).

Kar, A. et al. Improvement of oral cancer screening quality and reach: The promise of artificial intelligence. J. Oral Pathol. Med. 49, 727–730 (2020).

Alabi, R. O. et al. Machine learning in oral squamous cell carcinoma: current status, clinical concerns and prospects for future—et systematic review. Artif. Intell. Med. 115, 102060 (2021).

Wang, X. et al. A personalized computational model predicts cancer risk level of oral potentially malignant disorders and its web application for promotion of non‐invasive screening. J. Oral Pathol. Med. 49, 417–426 (2020).

de Souza, L. L. et al. Machine learning for detection and classification of oral potentially malignant disorders: a conceptual review. J. Oral Pathol. Med. 52, 197–205 (2023).

Elmakaty, I., Elmarasi, M., Amarah, A., Abdo, R. & Malki, M. I. Accuracy of artificial intelligence-assisted detection of oral squamous cell carcinoma: a systematic review and meta-analysis. Crit. Rev. Oncol./Hematol. 178, 103777 (2022).

Musulin, J. et al. An enhanced histopathology analysis: an ai-based system for multiclass grading of oral squamous cell carcinoma and segmenting of epithelial and stromal tissue. Cancers 13, 1784 (2021).

Tian, H., Zhang, M., Jin, G., Jiang, Y. & Luan, Y. Cu-MOF chemodynamic nanoplatform via modulating glutathione and H₂O₂ in tumor microenvironment for amplified cancer therapy. J. Colloid Interface Sci. 587, 358–366 (2021).

Tian, H. et al. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J. Hematol. Oncol. 15, 1–40 (2022).

Tian, H. et al. A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy. J. Colloid Interface Sci. 607, 1516–1526 (2022).

Tian, H. et al. A targeted nanomodulator capable of manipulating tumor microenvironment against metastasis. J. Control. Release 348, 590–600 (2022).

Zhu, Y. et al. Recent advances of nano-drug delivery system in oral squamous cell carcinoma treatment. Eur. Rev. Med. Pharmacol. Sci. 23, 9445–9453 (2019).

Gharat, S. A., Momin, M. M. & Bhavsar, C. Oral squamous cell carcinoma: current treatment strategies and nanotechnology-based approaches for prevention and therapy. Crit. Rev. Therapeut. Drug Carr. Syst. 33, 363–400 (2016).

Fan, H. et al. Light stimulus responsive nanomedicine in the treatment of oral squamous cell carcinoma. Eur. J. Med. Chem. 199, 112394 (2020).

Zheng, D.-W. et al. Biomaterial-mediated modulation of oral microbiota synergizes with PD-1 blockade in mice with oral squamous cell carcinoma. Nat. Biomed. Eng. 6, 32–43 (2022).

Mapanao, A. K., Santi, M. & Voliani, V. Combined chemo-photothermal treatment of three-dimensional head and neck squamous cell carcinomas by gold nano-architectures. J. Colloid. Interface Sci. 582, 1003–1011 (2021).

Reuter, J. A., Spacek, D. V. & Snyder, M. P. High-throughput sequencing technologies. Mol. Cell 58, 586–597 (2015).

Pillay, B. et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat. Rev. 42, 56–72 (2016).